PRESS RELEASEAB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER FORMALLY GRANTED IN THE UNITED ...
AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Paris, 13 May 2025, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces its ...
AB SCIENCE IS INVITED TO PRESENT AT THE 2026 ENCALS ANNUAL MEETING THE SURVIVAL DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS Masitinib treatment has been linked to a 5-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results